Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has won a government tender to be a primary supplier of medicinal cannabis oils for a national trial in France
  • The two-year trial will test the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients
  • As part of the trial, LGP will partner with leading pharmaceutical distributor, Intsel Chimos, who will undertake batch-release, distribution, medical information and drug safety obligations
  • Little Green Pharma will be responsible for manufacturing and supplying its medicines into France at its own cost
  • Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France — providing LGP with a “first-mover advantage”
  • Company shares are up 11.2 per cent and trading at 64.5 cents

Little Green Pharma (LGP) has been selected as a primary supplier of medicinal cannabis oils for a national trial in France.

Since 2018, the French National Agency for the Safety of Medicines and Health Products has been developing the tender for this two-year trial. The trial is aimed at testing the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients.

These patients will have varying conditions such as refractory neuropathic pain, drug-resistant epilepsy, intractable symptoms linked to cancer or anticancer treatment, palliative situations, or painful spasticity from multiple sclerosis or other issues within the central nervous system.

Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France.

The medicinal cannabis trial is in partnership with Intsel Chimos, a leading pharmaceutical distributor and recognised hospital partner in France.

Since 1966, the French company has specialised in importing and distributing medicines to hospitals and dispensaries across France.

Intsel Chimos’ role within the partnership involves undertaking batch-release, distribution, medical information and drug safety obligations. Meanwhile, LGP will be responsible for manufacturing and supplying its medicines into France at its own cost.

“We are very proud of our partnership’s success in the French national tender and see this tender win as strong evidence of LGP successfully implementing its export-led global sales strategy and demonstrating the benefits of Australian Good Manufacture Practices (GMP) quality manufacturing in global pharmaceutical markets,” Little Green Pharma Managing Director Fleta Solomon said.

Fleta also congratulated Intsel Chimos for developing a competitive bid for the tender and is looking forward to working together.

“We trust this marks the beginning of a long and rewarding partnership as we look to grow and cement our reputation amongst French patients and prescribers as a world-class medicinal cannabis supplier,” she said.

Significantly, this tender provides Little Green Pharma with a “first-mover advantage” in case medicinal cannabis does end up being legalised in France after the trial.

Company shares are up 11.2 per cent and trading at 64.5 cents at 1:31 pm AEDT.

LGP by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.